SML3126

BI-2852

≥98% (HPLC)

• Synonym(e): (3S)-2,3-Dihydro-5-hydroxy-3-[2-[[[[1-[(1-methyl-1H-imidazol-4-yl)methyl]-1H-indol-6-yl]methyl]amino]methyl]-1H-indol-3-yl]-1H-isoindol-1-one, (S)-5-Hydroxy-3-(2-(((1-((1-methyl-1H-imidazol-4-yl)methyl)-1H-indol-6-yl)methylamino)methyl)-1H-indol-3-yl)isoindolin-1-one, BI 2852, BI2852
• Empirische Formel (Hill-System): C₃₁H₂₈N₆O₂
• CAS-Nummer: 2375482-51-0
• Molekulargewicht: 516.59
• MDL-Nummer: MFCD32197229
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: O=C1C2=C([C@H](N1)C3=C(NC4=C3C=CC=C4)CNCC5=CC6=C(C=C5)C=CN6CC7=CN(C=N7)C)C=C(C=C2)O

Beschreibung

Biochem./physiol. Wirkung

BI-2852 is RAS inhibitor that binds RAS switch I and II (SI/II) pocket in both the active and inactive forms (GCP-/GDP-bound KD in μM = 0.74/2.0 (KRAS-G12D), 7.5/1.1 (KRAS), 0.57/2.5 (HRAS), 1.3/8.3 (NRAS)). BI-2852 inhibits RAS-mediated signaling and proliferation of KRAS-G12C-bearing NCI-H358 lung cancer cells (EGF-induced pERK IC50 = 5.8 μM; GI50 = 6.7 μM in soft agar with low serum) by blocking KRAS interactions with GEF SOS1 (GDP-bound G12C/G12D IC50 = 450/260 nM, GTP-bound Wt/G12C/G12D IC50 = 490/360/490 nM) and effectors CRAF (GTP-bound Wt/G12C/G12D IC50 = 1740/80/770 nM) and PI3Kα (GTP-bound Wt/G12C/G12D IC50 = 250/100/500 nM).

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable